Nucleofection-based screening of chimeric antigen receptor candidates in human natural killer cells
Chimeric antigen receptor (CAR)-modified cell therapy products approved for clinical treatment of hematological malignancies have hitherto been based on T cells. NK cells represent a promising immune cell type that can be considered for CAR engineering…